UK Health Security Agency
Immunisation and Vaccine Preventable Diseases
Prof Shamez Ladhani PhD MRCPCH(UK) MSc(distinction) MBBS(hons) BSc(hons) is a paediatric infectious diseases specialist at St. George’s Hospital, a reader in paediatric infectious diseases at St. George’s University of London and consultant epidemiologist at UK Health Security Agency (UKHSA), where he is the clinical lead for a number of national vaccine preventable infections, including Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis, which are all major causes of childhood bacterial meningitis. He completed his medical training at Guy’s and St. Thomas’s Hospitals, London, and then worked in a children’s hospital in rural Kenya. Upon returning to London, he obtained his PhD in genetic epidemiology and vaccine failure in children and completed his specialist paediatric infectious diseases training at St. George’s and Great Ormond Street Hospitals, London. In the current pandemic, he is the clinical lead for of SARS-CoV-2 surveillance in children at UKHSA. His work has focused on national surveillance of SARS-CoV-2, PIMS-TS and long COVID, immune responses to SARS-CoV-2 in children compared to adults, as well as infection, transmission and outbreaks in educational settings and COVID-19 vaccines for children
Moderator of 1 Session
Session Type
Meet-the-Expert Session
Date
Tue, 21.06.2022
Session Time
13:30 - 14:30
Room
Grand Ballroom West
Chair(s)
Session Description
In this session we will present data from our respective countries on the main serotypes that are emerging to be dominant in the post higher valency vaccine use era (i.e. post 13vPCV/10vPCV) and discuss the interpretation of that data in terms of serotype replacement.
We will touch on definitions and views on the possible mechanisms of serotype replacement. We will also focus on changes in serotype 3 disease, what effect COVID-19 pandemic would have had on serotype profile of pneumococcal disease and the place of new higher valency PCVs becoming available now (such as 15vPCV and 20vPCV) in addressing replacement disease.
We believe that this session will help attendees in interpreting pneumococcal disease epidemiology following vaccine use and understand changes in serotype distribution in the context of replacement. There will be learnings from the data we will discuss that mainly reflect what occurred in countries with mature PCV programs for other settings that have introduced PCVs more recently and also those yet considering PCV use.
Please note: All MTE sessions are designed to encourage active learning and to concentrate on close interaction between audience and speakers. The MTE session organisers have provided at least 15 minutes for active discussions in their agenda.
We will touch on definitions and views on the possible mechanisms of serotype replacement. We will also focus on changes in serotype 3 disease, what effect COVID-19 pandemic would have had on serotype profile of pneumococcal disease and the place of new higher valency PCVs becoming available now (such as 15vPCV and 20vPCV) in addressing replacement disease.
We believe that this session will help attendees in interpreting pneumococcal disease epidemiology following vaccine use and understand changes in serotype distribution in the context of replacement. There will be learnings from the data we will discuss that mainly reflect what occurred in countries with mature PCV programs for other settings that have introduced PCVs more recently and also those yet considering PCV use.
Please note: All MTE sessions are designed to encourage active learning and to concentrate on close interaction between audience and speakers. The MTE session organisers have provided at least 15 minutes for active discussions in their agenda.
Presenter of 1 Presentation
How Low Can You Go? Update on Use and Evaluation of a 1+1 Schedule (ID 44)
Session Type
Plenary Session
Date
Tue, 21.06.2022
Session Time
09:00 - 10:30
Room
Grand Ballroom East
Presenter
Lecture Time
09:30 - 10:00